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1. Introduction
MicroRNAs (miRNAs)are short 18–25 nucleotide small non-coding RNA molecules that
function to silence gene expression via sophisticated post-transcriptional regulation[1]. Since
their discovery in the early 1990s, these small molecules have been shown to play an important
regulatory role in a wide range of biological and pathological processes. Over 30% of human
messenger RNAs (mRNAs) are regulated by miRNAs[2]. miRNAs generated by the canonical
biogenesis pathway are transcribed as precursor RNAs from intergenic, intronic or polycis‐
tronic genomic loci by RNA polymerase II (Pol II). The primary miRNA (pri-miRNA) transcript
forms a stem–loop structure that is recognized and processed by the Drosha and DGCR8 RNase
III complex or the spliceosome apparatus in the nucleus. In the non-canonical miRNA
pathway, miRNAs are transcribed directly as endogenous short hairpin RNAs (endo-shRNAs)
or derive directly through splicing from introns that can refold into hairpins (mirtrons). The
trimmed precursor (pre-miRNA) hairpins from both canonical and non-canonical miRNA
pathways are then transported by an exportin 5 and RAN-GTP-dependent process to the
cytosol, where they are typically further processed by the Dicer and transactivation-response
RNA-binding protein (TRBP) RNase III enzyme complex to form the mature double-stranded
~22-nucleotide miRNA. Argonaute proteins (for example, AGO2)
then unwind the miRNA duplex and facilitate incorporation of the miRNA-targeting strand
(also known as the guide strand) into the AGO-containing RNA-induced silencing complex
(RISC). The RISC– miRNA assembly is then guided to specific target sequences in mRNAs.
The initial recognition of mRNAs by the RISC–miRNA complex is driven primarily by
Watson–Crick base-pairing of nucleotides 2 to 8 in the mature miRNA (termed the seed
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sequence) with specific mRNA target sequences chiefly located in the 3′ untranslated region,
and additional base-pairing affords greater affinity and targeting efficiency(Figure1)[3].
Given the pivotal regulatory role of miRNAs in a broad range of biological processes, it is not
surprising that miRNAs play a role in human cancers, including brain tumor. First, about 50%
of human miRNAs are located in cancer-associated genomic regions and fragile sites, sug‐
gesting that they might be the target genes underlying such aberrant intervals [5]. Second, the
advent of high-throughput detection method has promoted expression profiling of miRNAs
in normal and tumor tissues. Compared to normal tissues, anomalous levels of miRNA subsets
have been found in almost all tumor types examined [6, 7]. Third, miRNAs with tumor-
suppressive gene and oncogene-like properties have been described.
Since the first description of aberrant miRNA expression in glioblastomas and pituitary
adenomas in 2005 [8, 9], there have been increasing reports each year about miRNA deregu‐
lation and function in various brain tumors. In this chapter, we summarize the current findings
of miRNA study in brain cancers and discuss the diagnostic and therapeutic potential of
miRNAs, mainly in glioma.
Figure 1. The miRNA biogenesis pathway[4]
2. MiRNAs profile in brain tumor
CBTRUS obtained incidence data from 48 population-based cancer registries that include cases
of malignant and non–malignant (benign and uncertain) primary brain and central nervous
system tumors in the United States in 2004-2007. The most frequently reported histology is the
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predominately non–malignant meningioma, which accounts for 34% of all tumors, followed
by glioblastoma (17%). The predominately non-malignant pituitary and nerve sheath tumors
account for 13% and 9% of all tumors, respectively. Acoustic neuromas (defined by ICD-O-3
site code C72.4 and histology code 9560) account for 63% of all nerve sheath tumors(Figure2).
Only recently, the miRNAs attracted increasing attention as potential diagnostic or even
therapeutic tools in brain tumors. Profiling techniques to identify global expression patterns
of miRNAs in brain tumors have been widely used to uncover aberrantly expressed micro‐
RNAs in tumor genomes. Ciafrè et al. found nine (miR-10b, miR-130a, miR-221, miR-125b-1,
miR-125b-2, miR-9-2, miR-21, miR-25, miR-123) and four miRNAs (miR-128a, miR-181c,
miR-181a, miR-181b), respectively, out of 245 miRNAs to be up-/down-regulated in human
glioblastoma samples, and nine (miR-221, miR-23a, miR-24-2, miR-24-1, miR-23b,
miR-21,miR-222-prec, miR-191, miR-220) and seven miRNAs(miR-181a, miR-181b, miR-128b,
miR-197, miR-181c,miR-125b-2, miR-125b-1), respectively, to be up-/down-regulated in
human glioblastoma cell lines[10]. Chan et al.[8] demonstrated five (miR-21, miR-138, miR-347,
miR-291-5′, miR-135) and three miRNAs (miR-198, miR-188,miR-202), respectively, out of 180
miRNAs to be up- and downregulated in glioblastoma samples. Sasayama et al.[11] found
miR-10b, miR-21, miR-183, miR-92b and miR-106b to be up-, and miR- 302c*, miR-379, miR-329,
miR-134 and miR-369-3p to be downregulated in human glioblastoma samples. Other studies
reported several miRNAs to be significantly deregulated in glioma samples of Chinese patients
(including miR-34a, miR-15b, miR-200a and miR-146b) [12], or miR-29b, miR-125a and miR-149
to be downregulated in glioblastomas [13]. In an array study with 192 miRNAs, 13 miRNAs
(miR-101, miR-128a, miR-132, miR-133a, miR-133b, miR-149, miR-153, miR-154*, miR-185,
miR-29b, miR-323, miR-328, miR-330) were found to be downregulated and three miRNAs to
be upregulated (miR-21, miR-155, miR-210) in glioblastoma multiforme [14]. Another micro‐
array study identified 55 miRNAs out of 756 miRNAs to be upregulated and 29miRNAs to be
downregulated in malignant astrocytomas (primary and secondary glioblastoma and ana‐
plastic astrocytoma, respectively) compared to controls [15].
In additional to gliomas, miRNA profiling also had been discovered in some other brain
tumors. Ferretti et al were the first to identify signatures of a set of 248 miRNAs in a panel of
primary medulloblastomas and normal cerebellar controls using high throughput expression
profiles. They showed different expression profiles between normal brain and tumor and
between distinct tumor histotypes. In particular, they detected an upregulation of mir-21 and
miR-17-92 cluster (miR-17-5p, miR-20a and miR-19a) and a downregulation of miR-128a/b,
let-7, miR-124a, miR-103, miR-134, miR-138, miR-149, miR-181b, miR-9 and miR-125a, most of
them previously reported to be dysregulated in other brain tumor cell lines or nervous system
cancers [16]. Moreover, Recent microarray data reported a possible role of miRNAs in pituitary
adenomas. The first connection between pituitary adenomas and miRNAs was established by
Bottoni et al in 2005, that showed a downregulation of mir-15a and miR-16-1 in GH-secreting
and in PRL-secreting adenomas compared to normal pituitary tissue[8]. In 2007 Bottoni et al
explored the miRNAome of pituitary tumors by microarray. They found that 30 miRNAs are
differentially expressed between normal pituitary gland and pituitary adenomas. Among
them, miR-150, miR-152, miR-191, and miR-192 were found to be upregulated in pituitary
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adenomas, and miR-132, miR-128a, miR-136, miR-16-1, and let-7 are downregulated[17]. As
for meningioma, Feng Zhi et al found a list of 14 miRNAs that were differentially expressed
in meningioma compared to normal adjacent tissue(NAT)samples. Twelve miRNAs, including
miR-17-5p, miR-22-3p, miR-24-3p, miR-26b-5p, miR-27a-3p, miR-27b-3p, miR-96-5p,
miR-146a-5p, miR-155-5p, miR-186-5p, miR-190a and miR-199a were shown to be upregulated
by a factor greater than twofold, whereas two miRNAs, including miR-29c-3p and miR-219-5p,
were significantly downregulated[18].
3. Abberant miRNAs as prognostic and/or diagnostic marker for brain
tumor patients
The use of miRNAs as tumor biomarkers has gained growing interest in the last few years.
Accumulating evidence indicates that miRNA expression can be used as a prognostic and/or
diagnostic marker for brain tumor patients. Niyazi et al. separated 35 glioblastoma patients
into long- and short-term survivors. Then, they found that some miRNAs were significantly
different in two group, including miR-3163, miR-539, miR-1305, miR-1260 and let-7a. this is
the first dataset defining a prognostic role of miRNA expression patterns in patients with
glioblastoma[19]. Moreover, Ma also identified that MiR-196b is overexpressed and confers a
poor prognosis via promoting cellular proliferation in glioblastoma patients[20]. Costa et al
identified miRNAs that are over-expressed in ependymomas, such as miR-135a and
miR-17-5p, and downregulated, such as miR-383 and miR-485-5p. We have also uncovered
Figure 2. Distribution of All Primary Brain and CNS Tumors by Histology (N=226,791) CBTRUS Statistical Report: NPCR
and SEER Data from 2004-2007
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associations between expression of specific miRNAs which portend a worse prognosis. For
example, we have identified a cluster of miRNAs on human chromosome 14q32 that is
associated with time to relapse. We also found that miR-203 is an independent marker for
relapse compared to the parameters that are currently used. Additionally, we have identified
three miRNAs (let-7d, miR-596 and miR-367) that strongly correlate to overall survival[21].
4. Deregulated miRNAs regulated brain tumor cell phenotype
Increasing evidence supports the supposition that miRNAs play an important role in different
types of cancers and in various aspects of cancer biology. Abnormal miR levels in tumors have
important pathogenetic consequences: miRNAs may act as oncogenes or suppressor genes[22].
For examples, Calin et al. [23] identified two clustered miRNAs (miR-15a and miR-16-1) on
the minimal deletion region of chromosome 13q14 and showed that the levels of these miRNAs
were significantly reduced in the majority (68%) of B-cell chronic lymphocytic leukemia (CLL).
Both miRNAs target the anti-apoptotic gene BCL2, which is frequently overexpressed in CLL
[24]. These findings indicate that downregulation of miR-15a and miR-16-1 elevates BCL2
level, contributing to CLL formation and suggesting a tumor-suppressive role for both
miRNAs. In contrast, miR-17-92 showed marked upregulation in B-cell lymphomas. Enforced
expression of miR-17-92 cluster acted with c-myc to accelerate the onset of B-cell lymphoma
in a mouse model [25]. The data suggest that miR-17-92 cluster is a potential oncogene.
Recent evidence supports the ability of miRNAs to regulate brain tumor cell phenotype. We
had done some work to identified that miR-221 and miR-222 regulated their target expression
to co-modulated glioma cell phenotype, including proliferation, cell cycle, apoptosis and
invasion(Figure3)[26-28], and so on.
MiRNAs also regulated radio- and chemo-resistence of glioma. Hierarchical clustering
analysis of expression 1100 miRNAs in three glioma cell lines treated with clinically relevant
doses of radiation (2Gy) revealed significant (3-4 fold) up-regulation of several miRNA that
are implicated in stimulation of survival and proliferation of tumor cells [29]. The set of up-
regulated miRNAs includes miR-1285, miR-151-5p, and miR-24-1 that display beneficial effects
on tumors by inhibiting the core tumor suppressor p53 (miR-1285) and supporting migration,
local metastasis (miR-151-5p), and antiapoptosis (miR-24-1) [30]. Overall, activation of these
miRNAs might possibly increase tumor radioresistance in subsequent radiotherapy sessions
and stimulate motility of cancer cells thereby at least partially explaining the evidence on
enhanced migration of malignant glioma cells in response to radiotherapy [31]. The radiation
treatment of glioma cell lines with normal capacity to repair radiation-induced double strand
breaks (DSB) of DNA caused activation of let-7 [29], a family of miRNA that suppresses
proliferation of gliomblastoma cells [30] (Fig. 4). In contrast, in the radiosensitive human
glioma cell line M059J that is deficient in DNA-dependent protein kinase (DNA-PK) and has
a low activity of ATM, two key members of the non-homologous end joining pathway of DNA-
DSB repair, let-7 miRNA was down-regulated [30].
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Moreover, MiRNAs were shown to be also involved in the regulation of chemoresistence of
glioma by modulating some relevant proteins that are involved in drug metabolism and drug
transporter. MiRNAs also affect chemotherapeutic agents induced DNA damage repair (Fig. 4).
5. MiRNAs in gliomas and glioblastoma
MiRNAs affect biological character of varies cells by regulating their targets. So, deregulated
miRNAs regulated brain tumor cell phenotype by regulating their targets, including prolifer‐
ation, cell cycle, apoptosis, invasion, and so on.
Figure 3. miR-221 and miR-222 regulated their target expression to co-modulated glioma cell phenotype. (A: MTT
assay show that knockdown of miR-221/222 lowed proliferated rate of glioma cell; B: knockdown of miR-221/222
induce G1 arrest in glioma cell ;C: Annexin V analysis showed that knockdown of miR-221/222 significantly increased
glioma cell apoptosis; D: The transwell assay revealed that knockdown of miR-221/222 significantly decreased glioma
cell invasion.
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5.1. MiR-221 and miR-222
MiR-221 and miR-222 are both up-regulated in several glioma derived cell lines and in glioma
samples [26-28]. They are clustered within a 1-kb genomic interval on chromosome X, so they
could be generated from the same primary transcript [26].
Two members of the Kip/Cip family of CDK inhibitors and key negative regulators of the cell
cycle, p57 and p27, have been identified as putative direct targets of these miRNAs. According
to this theory, the 3'-UTR of p57 harbors one site expected to be recognized by both miR-221
and miR-222, whereas the 3'-UTR of p27 contains two sites for both miRNAs. Transfection of
both miR-221 and miR-222 greatly reduce the levels of p57 and p27 proteins, while downre‐
gulation of either microRNA 221 or 222 in glioblastoma cells caused an increase in p27 levels
and enhanced expression of the luciferase reporter gene fused to the p27 3'-UTR. These results
suggest that miR-221 and miR-222 could promote cell proliferation and S-phase entry together
with further cooperative events and that miRNA 221 and 222 inhibition may be a potential
therapeutic target to reduce the aggressive growth of glioblastoma by restoring normal levels
of their target proteins [32]. The inverse correlation between mir-221/222 and p27 levels, the
impairment of growth potential and the G1 to S shift in the cell cycle of glioma cells after
inhibition of mir-221/222, were later confirmed by Zhang et al. They extended their study to
in vivo trials and showed that miR-221/222 knocked-down through antisense oligonucleotides
Figure 4. MicroRNAs are involved in the regulation of DNA repair in cancer cells after treatment with ionizing radia‐
tion (radiotherapy) and DNA alkylating drugs such as temozolomide and carmistine[30].
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strongly reduced glioma subcutaneous mice xenografts growth through up regulation of p27
[26] and enhanced radiosensitivity of glioblastoma cell lines [33]. Further evidence showed
that knockdown of miR-221/222 induced a change of mitochondrial membrane potential and
caspase-mediated apoptosis on glioblastoma cells. Indeed, mir-221/222 directly downregulate
the proapoptotic protein PUMA, which leads in turn to decrease Bcl-2 and increase BAX. these
results confirm the oncogenic role of mir-221/222 on glioblastoma [27]. Our recent studies
identified that mir-221/222 increased cell invasion and reduced gap junction intercellular
communication (GJIC) by regulating TIMP3 and Cx43[28,34].
5.2. MiR-21
Microarray profiling studies, further validated by Northern blotting qRT-PCR and real-time
PCR analysis, showed that miRNA-21 is strongly elevated in glioma and glioblastoma tumor
samples and glioma cell lines when compared to non-neoplastic control samples, and upre‐
gulation is particularly prominent in grade IV astrocytomas [35-37]. High expression of miR-21
was significantly associated with poor patient survival, suggesting that, in combination with
other aberrant expressed miRNAs (low expression of miR-181b or miR-106a), miRNA-21
profiling has potential application as novel diagnostic and prognostic indicator [37].
Suppression of mir-21 in glioblastoma cells decreased the metabolic activity of cell culture and
cell number, and was associated with a marked increase in apoptosis and caspase activation
[35]. MiR-21 knockdown also leads to a considerable reduction of glioma volumes in mouse
xenografts [38]. Knockdown mir-21 inhibited proliferation and cell invasion and induced
apoptosis through the activation of caspase-3 and -9 in glioma cell lines, which may be related
to a mir-21-dependent modulation of multiple potential target genes, such as TIMP3 [39,40].
From an in silico constructed study of miR-21 predicted targets and further pathway analysis
of computer generated lists of the identified target genes, emerged that mir-21 targets multiple
components of the p53, transforming growth factor-β (TGF-β) and mitochondrial apoptosis
pathways, that contribute to its tumor promoting and antiapoptotic activity. The phenotypic
effects observed upon downregulation of miR-21 in glioblastoma cells, reflect the repression
of these pathways and result in significant increase in apoptotic cells, reduced growth and cell
cycle arrest at G0-G1 [41]. Further bioinformatics analysis evidenced that multiple genes
involved in apoptosis pathways (such as PDCD4, MTAP, and SOX5), carry putative miR-21
binding sites. PDCD4 mRNA is a direct functional target of miR-21 and its expression inversely
correlates with mir-21 in a number of glioblastoma cell lines (T98G, A172, U87, and U251).
Consistent with these observations, downregulation of mir-21 restored protein level of PDCD4
while, ectopic overexpression of mir-21, inhibits PDCD4-dependent apoptosis [42]. Mir-21
controls tumor invasiveness and microvascular proliferation by regulating the expression of
two of the major inhibitors of matrix metalloproteinases (MMPs): RECK and TIMP3. Mir-21
knockdown decreases RECK and TIMP3 protein levels and MMPs activity both in vivo and in
vitro leading to a reduction of glioma cell motility and invasion [43]. Although PTEN tumor
suppressor gene has been validated as a miR-21 target by computational analysis, down-
regulation of mir-21 leads to an inhibition of tumor growth in glioblastoma cell lines and
xenograft tumors independently of PTEN mutational status [44,45]. MiRNA expression profile
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scanning data after inhibition of miR-21, strongly indicated that BID, FAS, PRS6, and SOCS4
tumor suppressor genes were upregulated and evidenced a suppression of EGFR, activated
Akt, cyclin D, and Bcl-2. This study highlighted that miR-21 targets multiple pathways
responsible of inhibition of glioma growth in absence of PTEN [46].
Further findings strengthened the hypothesis that miR-21 represents a promising target to
improve the efficacy of chemotherapy. In a recent study mir-21 was shown to play a key role
in promoting human glioblastoma cells U87MG resistance against the antitumoral agent
temozolomide (TMZ). Indeed, ectopic overexpression of mir-21 significantly reduced TMZ-
induced apoptosis in this cell line through a suppression of Bax/Bcl-2 ratio and caspase-3
activity. These results confirm the hypothesis that mir-21 overexpression during glioma
progression could be responsible of clinical resistance to chemotherapy with the promising
alkylating agent TMZ [47]. Li et al demonstrated that mir-21 is also involved in glioblastoma
cell chemoresistance to the chemotherapeutic agent VM-26, as shown by the observation that
miR-21 knockdown sensitized GBM cells to VM-26. This is likely to happen because mir-21
regulates and inhibit LRRFIP1 gene expression by direct interaction [48]. This gene encodes a
protein, also known as the TRAF-interacting protein (TRIP), that inhibits NF-κB signaling, a
pathway that is known to be responsible for protection against apoptosis [49] and tumor
chemoresistance [50]. Additionally, suppression of miRNA-21 expression in glioblastoma cell
lines enhances sensitivity of cancer cells to antineoplastic cytotoxic therapy with neural
precursor cells (NPC) expressing a secretable variant of the cytotoxic agent tumor necrosis
factor related apoptosis inducing ligand (S-TRAIL). The synergistic effect was observed both
in vitro, through an increased caspase associated cytotoxic death, and in vivo, where miR-21
knockdown and NPC-mediated S-TRAIL reduce cancer growth in tumor xenografts [38]. A
recent study that evaluated the potential role of mir-21 as a therapeutic tool to enhance the
cytotoxic effect of standard chemotherapy showed that co-delivery of miR-21 and 5-fluorour‐
acil (5-FU) by using a poly(amidoamine) (PAMAM) dendrimer as a carrier, significantly
improved the cytotoxicity of the antitumor agent leading to an higher apoptosis rate and a
reduction of the migration ability of tumor cells [51]. Finally, downregulation of miR-21,
contributes to the antitumor effects of IFN-β on glioma cell and intracranial tumor xenografts
and the activation of the transcription factor STAT3 may have a key role in the IFN-β mediated
suppression of mir-21 [52].
5.3. Mir-34a
Mir-34a, transcriptional target of p53 located within chromosome 1p36, has been proposed as
a potential tumor suppressor. MiR-34a is also downregulated in glioblastoma tissues and cell
lines compared to normal brain tissues and is markedly reduced in p53-mutant cells compared
to cells expressing wild-type p53 [53,54].
MiR-34a possesses hundreds of predicted mRNA targets which could mediate its inhibitory
effects on tumor growth. A few of these have been experimentally verified and include
oncogenes such as MYC, CCND1, CDK6, SIRT1 [55] and c-Met [56]. It was shown to directly
inhibit c-Met in glioma and medulloblastoma cells and Notch-1/Notch-2 in glioma cells and
stem cells by binding to the 3'-UTRs of their mRNA. Furthermore, mir-34a inversely correlates
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with c-Met, Notch1, Notch2 and CDK6 protein expression in glioma cells. Transfection of
microRNA34a in brain tumor cells strongly inhibits cell proliferation, cell cycle progression,
cell survival, cell invasion, and in vivo glioma xenograft growth but do not affect cell cycle or
death when transfected to human astrocytes, which showed normal expression levels of
microRNA 34a. Restoration of c-Met or Notch-1 and Notch-2 expression by constructs lacking
3'-UTR regions partially reverted cell cycle arrest and apoptosis induced by miR-34a in glioma
cells or stem cells, confirming the hypothesis that the antitumor effects of miR-34a are achieved
via targeting of multiple oncogenes [53]. Interestingly, mir-34a also affect glioma stem cell
differentiation and growth. Luan et al recently reported silent information regulator 1 (Sirt1)
as a direct negative target of mir34a in glioma cell lines at a posttranscriptional level [54]. Sirt1
is a NAD-dependent deacetylase that regulates apoptosis in response to oxidative and
genotoxic stress, and has recently been involved in tumorigenesis acting as an oncogene [57].
5.4. Mir-128
Mir-128, a brain enriched microRNA, is downregulated in glioma cell lines and tissue when
compared to normal brain samples [58]. Mir-128 overexpression decreased glioma cell
proliferation in vitro and glioma xenograft growth in vivo, and is inversely correlated to Bmi-1
expression. Mir-128 directly targets and downregulates Bmi-1 by binding its 3'-UTR region
[59] and leads to a concomitant overexpression of p21CIP1 and a decrease in phosphorylated
Akt [58]. Bmi-1 expression is a critical factor of normal stem cell maintenance and glioblastoma
self-renewal and loss of Bmi-1-mediated self-renewal of neural stem cells has been shown to
be associated with upregulation of p21CIP1 [60] and decreased Akt activation [61]. Consis‐
tently with these observations, miR-128 overexpression in human glioma neurosphere cultures
possessing a glioma ‘stem-like’ cell phenotype, evidenced that miR-128 specifically blocked
glioma self-renewal reducing neurosphere number and size. In conclusion, mir-128 downre‐
gulation is likely to enhance glioma tumorigenesis by promoting an undifferentiated pheno‐
type and self renewing state through Bmi-1 increased expression [58]. By bioinformatical
analysis, E2F3a, a transcription factor involved in cell cycle progression [62], has been identi‐
fied as a direct target of this miRNA. Indeed, Mir-128 and E2F3a levels are negatively correlated
and mir-128 overexpression has similar inhibitory effects on proliferation of glioma cell lines
as E2F3a knocking down Ectopic overexpression of E2F3a partially reversed the effects of
mir-128, suggesting that mir-128 could exert its antitumor effects at least partially by inhibiting
E2F3a expression. Among its target genes angiopoietin-related protein 5 (ARP5) was identified
with bioinformatical tools and then confirmed to be inversely correlated to mir-128 levels in
glioblastoma cells and tissue and downregulated after ectopic overexpression of this miRNA
[58]. ARP5 seems to be a key regulator of cell proliferation, remodeling and regeneration [63]
and could be a member of a group of genes regulated by mir-128 that coordinately contribute
to glioma and GBM pathology [59].
5.5. Mir-451
Mir-451 was found to be upregulated in glioma samples compared to normal brain on
microarray-based miRNAome profiling [64]. MiR-451 showed a striking spatial distribution,
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with groups of positive cells concentrated around a subset of blood vessels. Moreover, high
levels of mir-451 are correlated to a poor prognosis in glioma patients. Mir-451 could regulate
the balance of proliferation and migration in glioma cells in response to changes in glucose
levels and metabolic stress. It regulates 5'-adenosine monophosphate activated protein kinase
(AMPK) pathway in response to glucose levels in glioma cells, through the modulation of the
activity of its upstream activator LKB1 [65]. Activation of LKB1 is a potent anti-proliferative
signal, and also influences cell polarity, a process known to affect cell motility [66].
MiR-451 regulates LKB1 activity by directly targeting CAB39, a component of the active
LKB1complex, leading to a downregulation of CAB39 protein levels. Down-regulation of
mir-451 levels in response to glucose deprivation leads to intense activation of LKB1 and
downstream pathways, allowing cells to survive metabolic stress and promoting cancer cell
migration. Conversely, when glucose is sufficient, elevated miR-451 levels lead to reduced
LKB1/AMPK pathway activation. This facilitates cell proliferation but makes cells more
sensitive to glucose deprivation. Thus mir-451 could be a key regulator of adaptive response
of cancer cells to altered energy availability [65].
In partial contrast with these studies a recent report found mir-451 to be downregulated in
glioma cell lines. Transfection of mir-451 to glioma cell lines was able to inhibit cell growth,
induced G0/G1 phase arrest, increased cell apoptosis and most notably diminished the invasive
capacity of these cells as evidenced by transwell invasion assay. These tumor suppressive
effects may be due to modulated expression of a panel of proteins including CyclinD1, p27,
MMP 2/9 and Bcl-2, probably via regulation of the PI3K/AKT signaling pathway. Indeed,
expression of Akt1 protein decreased after mir-451 transfection [67].
5.6. Mir-7
Mir-7, a miRNA modulated during neural differentiation of embryonic stem cells is a putative
tumor suppressor gene in glioblastoma. It inhibits EGFR gene expression by directly binding
its mRNA at 3'-UTR. Furthermore, miRNA-7 suppresses the activation of Akt pathway and
reduces phospho-Akt levels by directly targeting its upstream regulators IRS-1 and IRS-2 [68].
They also identified Raf1 as a direct target of miR-7 by microarray analysis, Western blot and
luciferase reporter assays of glioblastoma cells transfected with miR-7 [69]. Inhibition of Akt
activation seems to occur independently of mir-7-mediated repression of EGFR pathway.
Consistenly with these findings miRNA-7 was markedly downregulated in glioblastoma
tissue when compared to normal brain. The proposed mechanism that explains the lower
expression of this miRNA is a processing defect in generating pre-miR-7 from pri-miR-7 in
glioblastoma. Pre-miRNA-7 transfection decreased viability and invasiveness of glioblastoma
lines and glioblastoma derived stem cells and led to an increase in the sub-G0 apoptotic
fraction, a decrease in the S fraction and determined a G2-M arrest, most likely by affecting
EGFR and Akt pathways, which have an established key role in gliomagenesis [68]. Indeed,
EGFR is frequently amplified and highly expressed in glioblastomas [26]. In a recent report
mir-7 was also shown to directly inhibit p21-activated kinase 1 (Pak1) in non-brain cancer cells
[70]. Pak1 is a widely upregulated signaling kinase in multiple human cancers, and it is
involved in the regulation of many signaling pathways, including EGFR and Akt, thus
MicroRNAs Regulated Brain Tumor Cell Phenotype and Their Therapeutic Potential
http://dx.doi.org/10.5772/52362
507
interfering with cell motility, proliferation, and apoptosis [71]. Furthermore, in glioblastomas,
PAK1 upregulation is a negative prognostic marker and its knockdown results in impaired
cell invasion [72]. These preliminary results suggest mir-7 could have a potential and prom‐
ising therapeutic role in brain tumors.
5.7. Mir-181
Mir-181a and mir-181b are well known brain-enriched miRNAs [73]. Downregulation of
mir-181a and mir-181b was detected in both glioma samples and cell lines [74]. Transfection
of both these miRNAs on glioma cell lines results in cell growth inhibition, invasion reduction
and apoptosis induction, miR-181b being more effective than miR-181a [74]. In a recent miRNA
expression profiling conducted on a set of 124 astrocytoma samples and 60 normal adjacent
tissue samples by qRT-PCR, Zhi et al found that downregulation of miR-181b is significantly
associated with poor patient survival independently of other clinicopathological factors. Thus,
mir-181b has a great potential for being used as a diagnostic and prognostic marker and to
better select patients for adjuvant therapy [39].
In a recent study MiR-181b and miR-181c downregulation was found to be significantly
associated to a  positive response to concomitant  chemoradiotherapy with temozolomide
in glioblastoma patients,  suggesting they could be used as predictive factors for therapy
efficacy [75].
5.8. Mir-124/137
MiRNA-124 and miRNA-137 are downregulated in anaplastic astrocytomas and glioblastoma
multiforme relative to non-neoplastic brain tissue [9-10]. Consequently, growth factor signal‐
ing could promote brain tumor formation through suppression of miR-124 and/or miR-137
expression and inhibition of neural stem cells/tumor stem cell differentiation. Transfection of
mir-124 and mir-137 to neural stem cells and tumor-derived stem cells leads to induction of
cellular markers of differentiation, G1 cell cycle arrest and reductions of the expression of the
cell cycle regulator CDK6, a direct target of both miRNAs. These changes are accompanied by
reduced self-renewal and tumorigenicity. Overexpression of miR-124 or miR-137 also reduced
the expression of phosphorylated RB, a downstream target of CDK6 [76]. These results suggest
that ectopic expression of miRNA-124 and miRNA-137 could represent a valid therapy for
glioblastoma multiforme treatment inducing differentiation of tumor cells and cell cycle arrest.
5.9. MiR-125
Mir-125b downregulated in glioma cell lines after treatment with ATRA (all-trans-retinoic
acid), a regulator of neural differentiation and proliferation. Ectopic overexpression of
mir-125b stimulated glioma cell proliferation, partially recovering the cell growth inhibition
induced by ATRA treatment, while mir-125b knockdown promoted ATRA-mediated cell
apoptosis. Furthermore, Bmf was identified as a direct target of miR-125b, and they are
inversely correlated [77]. Bmf interacts with the prosurvival Bcl-2 proteins, regulating cellular
apoptotic pathways [78]. Indeed, transfection with miR-125b increase BCL-2 levels in glioma
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cells, and expression of BCL-2 was significantly decreased when cells were transfected with
miR-125b inhibitor. Thus, Bmf may play an important role in the process of miR-125b influ‐
encing cell apoptosis [77].
Recently, Cortez et al identified that mir-125a downregulated in glioblastomas and particulary
in glioma stem cells CD133+. Overexpression of mir-125a inhibits invasion properties of
glioblastomas, probably through a direct downregulation of podoplanin (PDPN), a membrane
sialo-glycoprotein related to invasion and malignancy [79].
5.10. MiR-326
Kefas et al evidenced a feedback loop between miRNA-326 and Notch pathway, frequently
deregulated in gliomas. Notch-1 knockdown induced mir-326 upregulation in glioma stem
cells, and ectopic overexpression of mir-326 decreased Notch pathway members level and
activity. Forced expression of mir-326 also inhibited cell proliferation, viability and invasive‐
ness and induced apoptosis in both established and stem cell-like glioma lines, these effects
are at least partially explained through downregulation of the Notch pathway. Moreover, it
reduced tumorigenicity in mouse glioma xenografts. Together with the observation that
mir-326 is downregulated in glioblastomas, these findings suggest that miR-326 is a potential
tumor suppressor in glioma cells and that reversing Notch/miR-326 axis toward miR-326
prevalence appears to be a potential therapy for brain tumors [80].
5.11. Mir-26a
Mir-26a up-regulated in high-grade gliomas. MiR-26a is a direct negative regulator of PTEN
and significantly represses PTEN expression. MiR-26a overexpression was attributed to the
amplification of miR-26a-2 locus (chromosome 12q), one of the two miR-26a loci present in the
human genome (mir-26a-1 and miR-26a-2) and is correlated with monoallelic PTEN deletion.
It was suggested a temporal sequence to the molecular evolution of miR-26a-amplified
gliomas, with PTEN loss most likely preceding miR-26a-2 amplification and, concordantly,
miR-26a overexpression in genetically engineered PTEN+/- mice precluded loss of their
remaining PTEN allele. Amplification of mir-26a is likely to promote the silencing of the
remaing PTEN transcript in PTEN+/- tumors, event analogous to a loss of heterozygosity.
Furthermore, in a murine glioma model, PTEN repression mediated by overexpression of
miR-26a, enhanced de novo tumor formation. Akt pathway activation and suppression of its
negative regulator PTEN are particularly important and frequently occur in glioma develop‐
ment. These observations document a new epigenetic mechanism for PTEN regulation in
gliomagenesis, further highlighting that dysregulation of Akt signaling is crucial to the glioma
development and could be modulated through manipulation of miRNA expression [64].
Moreover, MiR-26a is a frequent target of the 12q13.3-14.1 amplicon that also contain CDK4
and CENTG1, two oncogenes that regulate the RB1 and PI3 kinase/AKT pathways, respec‐
tively. The presence of this amplification is negatively correlated to patient survival. PTEN,
RB1, and MAP3K2/MEKK2 were detected as functional targets of mir-26a in glioblastoma.
Ectopic overexpression of miR-26a increased GBM cell growth, decreased apoptosis and
enhanced gliomagenesis in vivo. Thus, miR-26a decreases PTEN expression, activates AKT,
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and promotes tumor growth. Using human U87 GBM cells that lack functional PTEN, mir-26a
overexpression increased cell growth and decreased apoptosis despite the absence of PTEN,
most probably by downregulating RB1 and MAP3K2, a gene that encodes MEKK2[81]. MEKK2
is a mitogen-activated protein kinase kinase involved in JNK activation pathway that promote
apoptosis in GBM cells [82].
5.12. Mir-10b
Mir-10b is upregulated in glioma samples and glioma cell lines compared to non-neoplastic
brain tissues. RhoC and urokinasetype plasminogen activator receptor (uPAR), which are
known to contribute to glioma invasion and migration, were correlated with mir-10b expres‐
sion in gliomas, probably via inhibition of the translation of the mRNA encoding homeobox
D10 (HOXD10], which in turn represses the expression of these genes [83]. These results
suggest that mir-10 could be involved in regulation of the invasion and migration abilities of
gliomas.
5.13. Mir-15b
Mir-15b was shown to be elevated in a panel of glioma cell lines. Transfection of glioma cells
with miR-15b significantly increased G0/G1 cells and decreased the percentage of cells in S
phase, while inhibition of mir-15b increased G0/G1 cell amount. Thus, miR-15b regulates cell
cycle progression in glioma cells by targeting cell cycle-related factors as CCNE1 (cyclin E1],
a validated downstream target of mir-15b [84].
5.14. Mir-146b
Mir-146b, a miRNA found to be downregulated in human glioma tissue, could exert an
antitumor activity by reducing the expression of a matrix metalloproteinase gene, MMP16, one
of its direct downstream targets. Indeed, transfection of U373 glioma cells with miR-146b
precursor decreased tumor cell migration and invasion, while inhibition of miR-146b by LNA
modified anti-miR-146b produced the opposite effect, without affecting cell proliferation [85].
5.15. Mir-296
Recent studies support a role of mir-296 in promoting angiogenesis in gliomas. When brain mi‐
crovascular endothelial cells were co-cultured with U87 glioma cells or when vascular endothe‐
lial growth factor (VEGF) was added to cultured human brain microvascular endothelial cells,
miR-296 was upregulated. Moreover, mir-296 levels were higher in endothelial cells isolated
from human brain tumors compared to normal brain endothelial cells. Downregulation of
miR-296 in endothelial cells resulted in the inhibition of morphologic characteristics associated
with angiogenesis and reduced angiogenesis in glioma xenografts in vivo. This probably hap‐
pens through the downregulation of the hepatocyte growth factor-regulated tyrosine kinase
substrate (HGS), a validated target of mir-296, thus leading to a reduced HGS-mediated degra‐
dation of the platelet derived growth factor receptor (PDGFR) and vascular endothelial growth
factor receptor (VEGFR). This result points out an interesting feedback loop, where VEGF indu‐
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ces miR-296 expression, which in turn increases cell response to VEGF. Consequently, manipu‐
lating mir-296 expression, could enable to control a key step in cancer angiogenesis [86].
5.16. Mir-29
Mir-29b was found to be significantly downregulated in glioblastoma samples and cells and
CD133+ tumor stem cells. Forced overexpression of this miRNA inhibited invasion and
proliferation and induced apoptosis in glioblastoma cells. Mir-29b as well mir-125a directly
targets podoplanin (PDPN), a putative marker of neural stem cells, related to invasion and
malignancy in glioblastoma [13].
5.17. MiR-17-92 cluster
MiR-17-92 cluster, located within the locus 13q31-q32, encloses five miRNAs (miR-92-1,
miR-19a, miR-20a, miR-19b, miR-17-5p), which have been frequently involved in tumorigen‐
esis [87]. This cluster was detected to be amplified in glioblastoma samples. Furthermore,
expression of miR-17-92 cluster is downregulated upon induction of differentiation of GBM
spheroid cultures by using ATRA. Induction of differentiation leads to deregulation of most
of the key pathways associated with self-renewal such as insulin-like growth factor 1 signaling,
vitamin D receptor/retinoic acid X receptor activation, Wnt/β-catenin signaling and retinoic
acid receptor activation. Inhibition of miR-17-92 cluster leads to decreased cell viability and
decreased cell proliferation probably through a de-repression of CDKN1, E2F1, PTEN and
CTGF which are upregulated. Particularly, connective tissue growth factor (CTGF) gene was
shown to be a direct target of miR-17-92 in glioblastoma spheroids by luciferase reporter assays
[88]. CTGF binds vascular endothelial growth factor (VEGFA), which is a central mediator of
angiogenesis [89], and inhibits VEGFA-induced angiogenesis [90]. Conversely, VEGFA was
shown to inhibit MiR-17-92 [91], thus explaining the concomitant downregulation of VEGFA
and miR-17-92 upon induction of differentiation. In conclusion, the interaction between CTGF,
VEGFA and miR-17-92 might have a key role in gliomagenesis by targeting multiple regulatory
pathways [88].
5.18. Let-7
Let-7 expression is not downregulated in human glioblastoma tissues and cell lines, let-7
ectopic overexpression by transfection on U251 and U87 human glioblastoma cells, reduced
in vitro proliferation and migration and also in vivo tumor growth after xenotransplantation
into nude mice. Furthermore, let-7 miRNA reduced the expression of total RAS, N-RAS, and
K-RAS in glioblastoma cells [92]. These results suggest that let-7 miRNA is able to impair
glioblastoma growth and cellular migration via RAS inhibition.
6. MicroRNAs and tumor stem cells
Glioma stem cells (GSCs) have been recently identified [93]. They express common neural stem
cell (NSC) markers (CD133, Nestin, Musashi, and Sox2) and display multiple-lineage differ‐
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entiation potential and a greater tumorigenic activity in rodent xenografts. GSCs also show an
increased angiogenic potential through a higher expression of vascular endothelial growth
factor (VEGF). GSCs are strongly resistant to radiation [94]and chemotherapy [95].
A recent study by Lavon et al showed a similar expression pattern of mir-21, mir-124, and
mir-137 in gliomas and stem cells. Among them we mention the miR-17 family cluster that
contains 3 miRNAs upregulated in gliomas and NPCs (mir-17-92, mir-106b-25, mir-106a); the
mir-183-182 cluster, also upregulated in gliomas and NPCs; the large 7+46 bipartite miRNA
cluster on chromosome 14, as most of miRNAs located within this region have been shown to
be downregulated in the same samples [96]. This latter cluster is located within a region which
shows a frequent loss of heterozygosity in glioblastomas [97]. Finally, mir302-367 cluster on
chromosome 4q25 and mir371-373 cluster on chromosome 19q13, are upregulated in gliomas
and NPCs. These data confirm the hypothesis that brain cancers arise from multipotent GSCs,
thus explaining the phenotypic heterogeneity of tumors.
Many groups investigated the role of miRNAs in GSCs so far: in a first report Silber et al found
that mir-124 and mir-137 are reduced in grade III and IV gliomas compared to normal brain.
Besides, transfection of these two miRNAs in neural stem cells and glioma cancer cell lines
leads to induction of cellular markers of differentiation, G1 cell cycle arrest and reductions of
CDK6, thus indicating a hypothetical tumor suppressor role of micro-124 and microRNA-137
in GSCs [29]. As previously mentioned in this review, mir-128 was identified as a negative
regulator of glioma self renewal when ectopically overexpressed on human glioma neuro‐
sphere cultures [58].
A recent analysis showed that mir-451 is significantly downregulated in CD133+cells. Trans‐
fection of miR-451 inhibits proliferation and neurosphere formation in GSCs, highlighting that
it can act as a tumor suppressor: two target sites for SMAD protein in the upstream promoter
region of miR-451 have been found, leading to draw the conclusion that this miRNA is
activated by SMAD pathway. Transfection of SMAD in GBM cells inhibited their growth,
suggesting it could induce differentiation of glioma CD133+stem cells through up-regulation
of miR-451, thus reducing their tumorigenicity [98].In conclusion, a stable and selective
delivery of these miRNAs to GSCs could represent a great advance for brain tumor therapy.
MiR -125b is required for stem cell fission, allowing them to bypass the G1/S checkpoint and
making them insensitive to chemotherapy [99]. It has been found to be significantly downre‐
gulated in CD133+glioma stem cells compared to CD133-ones, leading to the hypothesis that
it may be involved in cell differentiation. As expected, transfection of mir-125b to CD133+cells,
decreased the number of proliferating cells and induced G0-G1 arrest: this effect occurs
through a mir-125b-dependent downregulation of CDC25A and CDK6, two cell cycle regula‐
tory proteins [47]. Moreover, miR-29b and miR-125a, are under-expressed in glioblastoma
CD133+cells compared with their counterpart CD133-cells (see above), suggesting a potential
role for these microRNAs in regulation of signaling pathways related to maintenance of stem
cell properties and self-renewal of cancer cells [79].
Some miRNAs could have a role in the regulation of key pathways of GSCs. We already
mentioned above the existence of a regulatory feedback loop between the tumor suppressor
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mir-326 and Notch pathway, shifted towards a prevalence of Notch activity in brain tumor
cells and GSCs [80] Recently, pyruvate kinase type M2 (PKM2) has been identified as a putative
target of mir-326, as levels of PKM2 and mir-326 are inversely correlated in glioma cells. PKM2,
highly expressed on cancer cells and GSCs, plays the role of mediator in mir-326 metabolic
effects: experimental knockdown of this molecule led to an impairment of glioma invasiveness
and clonogenicity and decreased ATP levels, suggesting that PKM2 could represent a valid
target for glioma therapy [100].
Mir-34a downregulated in gliomas and GSCs. When transfected into GSCs, it decreased the
expression of the stem cell markers CD133 and nestin and caused an higher immunostaining
for astrocytes and oligodendrocytes markers, besides modestly inhibiting several malignancy
end-points (migration, survival, proliferation, cell cycle progression). Remarkably, miR-34a
levels in glioma stem cells are significantly lower than in differentiated wild-type p53 glioma
cell lines, suggesting that restoration of miR-34a expression for therapeutic purposes could
achieve strong anti-tumor effects not only by targeting differentiated glioma cells, but also by
inducing glioma stem cell differentiation [56].
7. MicroRNAs in medulloblastoma
Medulloblastoma (MB) is the most common brain malignancy observed in childhood (WHO
grade IV) [101]. Ferretti et al were the first showed that miRNAs profiles is different between
primary medulloblastomas and normal cerebellar controls. These aberrant miRNAs have a
potentially role in MB development: e.g., let-7 microRNAs has been shown to inhibit Ras
oncogene expression [102], reported to be a key factor for MB metastatic behavior [103];
miR-17-92 cluster cooperates with myc, frequently overexpressed in MB, to induce neoplastic
transformation [104]; miR-9 and miR-125a, both downregulated in MB, are involved in cell
proliferation and, when transfected into MB cells, promote apoptosis and impair anchorage-
independent growth by downregulating the truncated isoform of the neurotropin receptor
TrkC (t-TrkC). T-TrkC expression levels are higher in MB, inversely correlate with miR-9 and
miR-125a levels and are responsible of enhanced cell proliferation and worse prognosis. Mir-9
and mir-124 have a common molecular target, REST/NRSF (RE1 silencing transcription factor/
neuron-restrictive silencer factor) complex [105]. These observations suggest that Mir-9 and
mir-124 could play an important role in cerebellar tumorigenesis as REST inactivation has been
reported to inhibit tumor growth [106] and is overexpressed in many MBs [107]. Consequently,
a REST/mir-124 axis shifted towards a prevalence of REST activity, could block neuronal
differen-tiation and promote neoplastic transformation [108].
Mir-124 also modulates medulloblastoma growth by targeting CDK6, a key pro-proliferative
factor overexpressed in 30% of medulloblastomas, which represents an adverse prognostic
marker for clinical outcome [109]. The role of mir-124 in MB development was later confirmed
by Li et al who additionally demonstrated that ectopic expression of mir-124 in medulloblas‐
toma cell lines inhibits cell growth by directly targeting SLC16A1, a protein upregulated in
MBs, that serve as a carrier to export lactic acid extracellularly, thus maintaining homeostasis
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of tumor cells, where aerobic glycolysis is known to be accelerated [110].At the same time,
downregulation of miR-218 could account for an overexpression of the pro-oncogene EGFR,
which activates MAPK pathway and CTNND2, which in turn encodes the gene of β-catenin
that activates the APC/Wnt signal transduction pathway and leads to tumor growth [111].
Hedgehog (Hh) patched (Ptch1) signalling pathway is a key regulator of the development of
cerebellar granule cell progenitors and its constitutive activation makes cells susceptible of
malignant transformation into medulloblastoma [112]. Hh is a secreted protein that binds to
the transmembrane receptor Ptch1 transducing an intracellular signal through the protoon‐
cogene Smoothened (Smo) to the downstream transcription factors Gli1, Gli2, and Gli3 [113].
Ferretti et al found that miR-125b, miR-326 and miR-324-5p target and repress activator
downstream components of the Hh signalling pathway (Smo and Gli1); consistent with these
findings, 50% of MBs showed a downregulation of these miRNAs together with an overex‐
pression of Gli1. Deletion of chromosome 17p, the most frequent mutation in medulloblasto‐
ma, could account for several genetic defects, including miR-324-5p, p53 and HIC1 tumor
suppressors loss, which cooperate in Hh-dependent tumorigenesis: loss of these genes,
together with other molecular events, contribute to a persistent hyperactivation of Hh
signalling during cerebellar granule cell progenitors development, leading to higher prolifer‐
ative activity and susceptibility to malignant MBs [114].
Recently, Hedgehog signalling pathway has been identified as a target of miR-17-92 cluster.
Indeed, miRNAs from the miR-17-92 cluster are specifically overexpressed in mouse MB
models with specific initiating mutations in Ptch1 and in human MB subgroups with an
activated SHH signaling pathway. To evaluate its oncogenic potential, miR-17-92 was
retrovirally transduced into mouse granule neuron progenitors cells (GNPs) before orthotopic
transplantation into immunocompromised mice. Interestingly, only cells with an SHH
signaling defect (Ptc+/-) developed MBs. Tumor cells from this model exhibited markers of
activated SHH signaling as elevated Math1 and Gli1 mRNA levels, and lost expression of the
wild-type Ptc allele, reinforcing the hypothesis of a functional link between the SHH pathway
and this miRNA cluster [115]. Some studies showed that miR-17-92 is most highly expressed
in SHH-driven medulloblastomas, and higher levels of miR-17-92 are also related to an
overexpression of the oncogene MYC. Moreover, transfection of miR-17-92 maintains mouse
CGNP cells in a proliferative state in the absence of SHH, and synergizes with SHH to promote
cell growth, while treatment of the same cells with SHH results in upregulation of miR-17-92,
confirming that this cooperation is crucial in MB tumorigenesis [116].
Notch pathway plays a key role in regulating granule-cell progenitor differentiation and an
increased copy number of Notch-2 was detected in 15% of medulloblastomas [117]. Expression
of the downstream effector of Notch, HES1, normally declines during neuronal differentiation,
while persistent activation of this factor prevents differentiation of precursor cells [118]. Garzia
et al identified mir-199-5p as capable of directly targeting and repress expression of HES1 in
MB cell lines. Ectopic expression of this miRNA reduced MB cell proliferation, population
expressing stem cell marker CD133 and xenograft tumor growth in mouse models. Their
studies also suggest that the documented downregulation of miR-199b-5p in metastatic tumors
may be related to epigenetic silencing [119].
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Venkataraman et al recently showed that several miRNAs known to be involved in CNS
development, are downregulated in medulloblastoma cell line cultures and tissues. A specific
one, miR-128a, is able to decrease tumor growth and proliferation if ectopically re-expressed
on MB cells. Bmi-1 has been identified as a putative target of miR-128a, a critical factor in
cerebellar development frequently upregulated in MBs. MiR-128a seems to normally down‐
regulate Bmi-1 oncogene, leading to increased levels of p16, a cell cycle inhibitor. Furthermore,
Bmi-1 could be involved in regulating reactive oxygen species by decreasing superoxide
generation, thus leading to a lower redox state in cancer stem cells [120]; this event is known
to be partially responsible of tumor resistance against common therapies [121].
Finally, mir-34a appeared to be a tumor suppressor gene also in medulloblastomas other than
in glioblastomas. Indeed, transient transfection of miR-34a into medulloblastoma cell lines,
strongly inhibited cell proliferation, cell cycle progression, cell survival and cell invasion most
probably through a direct inhibition of c-Met [56].
8. MiRNAs in pituitary tumors
Pituitary adenomas are benign and frequent neoplasms, accounting for about 15% of primary
intracranial tumors [122]. Bottoni et al found that 30 miRNAs are differentially expressed
between normal pituitary gland and pituitary adenomas. Furthermore, their expression is
inversely correlated with tumor size. They probably act through a negative regulation of RARS
(arginyl-tRNA synthetase), which is in turn upregulated in pituitary adenomas and modulates
the expression of factors influencing pituitary tumor growth [123]. Mir-15a and mir-16-1 are
located within chromosome region 13q14. Interestingly, loss of 13q region of chromosome 13
was frequently detected in pituitary tumors, confirming that this region likely contains tumor
suppressor genes [124].
These findings support the hypothesis that miRNA-16-1 plays a key role in tumor growth [195],
most probably by interacting with BCL2 [125], which is overexpressed in about one third of
pituitary adenomas [126]. MiRNAome could also function as a signature for specific histotypes
of pituitary adenomas. Overexpression of miR-23a, miR-23b, and miR-24-2 and lower expres‐
sion of mir-26b are more typical of GH-secreting and PRL-secreting adenomas, differentiating
them from non-functioning adenomas (NFA), characterized by mir-26 upregulation and
miRNA-24-2 downregulation. Moreover, NFA express higher concentration of miR-137 and
lower of miR-127, miR-129, miR-203, and miR-134 compared to GH-secreting adenomas.
Finally, ACTH-secreting adenomas are defined by a strong expression of mir-30 cluster
(miR-30a, miR-30b, miR-30c, and miR-30d), supporting the hypothesis that miRNAs could be
useful diagnostic markers to distinguish pituitary tumor histotypes [127].More recently,
Amaral et al evaluated the expression of microRNAs in ACTH-secreting pituitary tumors: they
found that let-7a, miR-21, miR-141, miR-143, miR-145, and miR-150, besides miR-15 and
miR-16, are downregulated in corticotropinomas compared to normal pituitary tissue and that
a lower expression of mir-141 is linked to a better chance of remission after surgery [128].
Moreover, downregulation of Mir-143 could be involved in tumorigenesis by activating MAPK
pathway via ERK5 [129].
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Quian et al showed that let-7 expression is decreased in more than one third of pituitary
adenomas and is related to higher tumor grade, thus it may act as a tumor suppressor. Levels
of let-7 were found to be inversely correlated to HMGA2 expression [130], confirming some
previous studies which showed that HMGA2 is repressed by let-7 [131]. High levels of HMGA2
have been detected in most types of pituitary adenomas [132] and they are significantly
associated with tumor grade, extent of invasion, tumor size and Ki-67 proliferation index,
probably through regulation of E-cadherin, E2F1, cyclin A, and p53 expression. Accordingly,
let-7 may be useful as a novel anticancer agent in the future [130]. A recent study on the role
of miRNAs in NFAs and GH-secreting pituitary tumors was performed by Butz et al, showing
that a group of miRNAs (miR-128a, miR-155, and miR-516a-3p) targets the 3'-untranslated
region of Wee1, a nuclear protein kinase that acts as a tumor suppressor, and which was found
to be significantly decreased in pituitary tumor samples [133].
9. Therapeutic potential of miRNAs
Current evidence indicates that miRNA deregulation is common in human cancers. The
discovery of miRNAs with oncogenic or tumor-suppressive function raises the possibility of
exploiting these RNA molecules for therapeutic intervention and the development of novel
therapies. The oncogenic miRNAs can be downregulated using antisense miRNA oligonu‐
cleotides (AMOs or antagomirs) or miRNA sponges[134,135], whereas tumor-suppressive
miRNAs may be targeted by replacement with miRNA mimetics.
AMOs  are  synthetic  oligonucleotides  with  sequence  complementary  either  to  mature
miRNA or its precursor and have been widely used to inhibit miRNA activities in vitro
and in vivo[136]. A number of chemical modifications to AMOs have been developed to
improve specific binding to target miRNAs and to resist nuclease degradation. These in‐
clude modifications at the 20-hydroxyl position (20-O-methyl (20OMe),  20-Omethoxyeth‐
yl(20MOE),  20-fluoro  (20F)  and  locked  nucleic  acids  (LNA)),  on  the  phosphorothioate
backbone,  and  conjugation  with  cholesterol  [137].  Of  these  modifications,LNA  shows
high  stability,  strong  affinity  for  target  miRNAs  and  low  toxicity  in  biological  system
and has emerged as a strong candidate for targeting miRNAs in vivo.  One clinical  trial
using  LNA  anti-miRNA  in  treating  human  disease  has  been  initiated  recently.  Using
LNA antimiR-21, Corsten et al. demonstrated that miR-21 knockdown in glioma cells led
to  an  increase  of  apoptotic  cell  death  and  a  significant  reduction  of  glioma  growth  in
vivo,  suggesting that  miR-21 is  a  potential  therapeutic  target.  They further showed that
combination of miR-21 suppression and the cytotoxic agent tumor necrosis factor-related
apoptosis-inducing ligand (TRAIL) resulted in enhanced caspase activity and synergistic
killing of glioma cells in vitro. When these treated glioma cells were implanted intracra‐
nially  into  nude mice,  tumor  cells  were  completely  eradicated  after  day  6  of  implanta‐
tion,  compared  to  reduced  tumor  volume  with  either  treatment  alone.  This  finding
suggests that miR-21 knockdown sensitizes glioma cells to apoptosis agent,  and that the
combined treatment is a promising approach for glioma elimination [138].
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Angiogenesis is a process essential for malignant glioma growth. By co-culturing glioma cells
with microvascular endothelial cells, Wurdinger et al. showed that glioma cells could induce
changes of miRNA expression in endothelial cells, with miR-296 being significantly upregu‐
lated. Enhanced expression of miR-296 was also observed in endothelial cells treated with
glioma-conditioned medium or proangiogenic growth factor VEGF or EGF, as well as in
endothelial cells isolated from glioma samples. These results suggested a role for miR-296 in
angiogenesis. It was further demonstrated that miR-296 contributed to angiogenesis by
targeting hepatocyte growth factor-regulated tyrosine kinase substrate (HGS), which controls
the levels of growth factor receptors (VEGFR2 and PDGFRb) by directing these macromole‐
cules to lysosomes for degradation. Importantly, intravenous administration of antimiR- 296
AMO significantly reduced angiogenesis in glioma xenografts in vivo[139]. These results
suggest that inhibition of angiogenesis by targeting miR-296 in endothelial cells may represent
an alternative approach in glioma therapy.
10. Conclusion
MiRNAs are an astonishing new class of gene regulators, and it had been demonstrated
that these molecules play a crucial role in cancer development and progression in a vari‐
ety of malignancies, including brain tumors. Most importantly, in a clinical context, there
is  first  evidence  that  miRNAs  might  provide  new  options  to  improve  diagnostics  and
therapy in the two most common malignant primary brain tumors in adults (glioblasto‐
ma)  and  children  (medulloblastoma).  In  vitro  and  in  vivo  data  suggest  that  miRNAs
could be used to discriminate brain tumors from normal brain tissue, and to identify dif‐
ferent astrocytoma grades. More important, clinico-pathological features seem to correlate
with miRNA expression in these tumors.  Furthermore,  there  is  increasing evidence that
miRNAs might help to generate targeted therapies and to overcome resistance to conven‐
tional anticancer strategies for example in glioblastomas. Of course, it has to be acknowl‐
edged  at  this  stage  that  translation  of  these  preliminary  “in  vitro  data”  into  “hard
clinical facts” is not feasible. But these findings provide a very promising basis for future
studies to determine the effect of miRNA modulation on chemotherapy in “in vivo stud‐
ies”.  Although  therapeutic  delivery  of  miRNAs  is  still  a  developing  field,  and  there  is
much more work to  be  done before  these  molecules  can be  securely  applied in  clinical
settings,  miRNA modulation may one day have a therapeutic application in patients.  In
summary,  the  presented  data  supports  the  enormous  clinical  potential  of  miRNAs  in
brain tumors, and mandate further intensive investigations in this field.
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